Shanghai Haohai Biological Technology 관리

관리 기준 확인 4/4

Shanghai Haohai Biological Technology CEO는 Jianying Wu, Jul2010 에 임명되었습니다 의 임기는 14.42 년입니다. 는 HK$ 501.74M 가치에 해당하는 회사 주식의 3.69% 직접 소유합니다. 501.74M. 경영진과 이사회의 평균 재임 기간은 각각 10 년과 11.1 년입니다.

주요 정보

Jianying Wu

최고 경영자

CN¥1.9m

총 보상

CEO 급여 비율	n/a
CEO 임기	14.4yrs
CEO 소유권	3.7%
경영진 평균 재임 기간	10yrs
이사회 평균 재임 기간	11.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jianying Wu 의 보수는 Shanghai Haohai Biological Technology 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	CN¥430m
Jun 30 2024	n/a	n/a	CN¥446m
Mar 31 2024	n/a	n/a	CN¥432m
Dec 31 2023	CN¥2m	n/a	CN¥416m
Sep 30 2023	n/a	n/a	CN¥346m
Jun 30 2023	n/a	n/a	CN¥315m
Mar 31 2023	n/a	n/a	CN¥226m
Dec 31 2022	CN¥2m	CN¥855k	CN¥180m
Sep 30 2022	n/a	n/a	CN¥203m
Jun 30 2022	n/a	n/a	CN¥192m
Mar 31 2022	n/a	n/a	CN¥272m
Dec 31 2021	CN¥1m	CN¥845k	CN¥352m
Sep 30 2021	n/a	n/a	CN¥428m
Jun 30 2021	n/a	n/a	CN¥434m
Mar 31 2021	n/a	n/a	CN¥370m
Dec 31 2020	CN¥1m	CN¥768k	CN¥230m
Sep 30 2020	n/a	n/a	CN¥232m
Jun 30 2020	n/a	n/a	CN¥216m
Mar 31 2020	n/a	n/a	CN¥279m
Dec 31 2019	CN¥2m	CN¥742k	CN¥371m
Sep 30 2019	n/a	n/a	CN¥353m
Jun 30 2019	n/a	n/a	CN¥386m
Mar 31 2019	n/a	n/a	CN¥375m
Dec 31 2018	CN¥1m	CN¥712k	CN¥415m
Sep 30 2018	n/a	n/a	CN¥411m
Jun 30 2018	n/a	n/a	CN¥408m
Mar 31 2018	n/a	n/a	CN¥390m
Dec 31 2017	CN¥1m	CN¥583k	CN¥372m

보상 대 시장: Jianying 의 총 보상 ($USD 260.96K ) Hong Kong 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 511.75K ).

보상과 수익: Jianying 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jianying Wu (60 yo)

14.4yrs

테뉴어

CN¥1,904,800

보상

Dr. Jianying Wu has been General Manager of Shanghai Haohai Biological Technology Co., Ltd. since July 23, 2010 and has been its Executive Director since December 2014. Mr. Wu served as a Director at Shang...

리더십 팀

이름	위치	테뉴어	보상	소유권
Yongtai Hou	Executive Chairman	14.4yrs	CN¥1.89m	3.65% HK$ 496.6m
Jianying Wu	GM & Executive Director	14.4yrs	CN¥1.90m	3.69% HK$ 501.7m
Minjie Tang	CFO & Executive Director	8yrs	CN¥1.45m	0.036% HK$ 4.9m
Yiyi Chen	Executive Director	10yrs	CN¥1.26m	0.26% HK$ 35.1m
Min Tian	Joint Company Secretary	5yrs	CN¥868.70k	0.0044% HK$ 601.1k
Caixia Ren	Deputy General Manager	10.3yrs	CN¥912.50k	0.012% HK$ 1.6m
Ming King Chiu	Joint Company Secretary	10.1yrs	데이터 없음	데이터 없음

10.0yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: 6826 의 관리팀은 노련하고 경험 (평균 재직 기간 10 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yongtai Hou	Executive Chairman	14.4yrs	CN¥1.89m	3.65% HK$ 496.6m
Jianying Wu	GM & Executive Director	14.4yrs	CN¥1.90m	3.69% HK$ 501.7m
Minjie Tang	CFO & Executive Director	7.8yrs	CN¥1.45m	0.036% HK$ 4.9m
Yiyi Chen	Executive Director	14.4yrs	CN¥1.26m	0.26% HK$ 35.1m
Hongbo Shen	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음
Jie You	Non Executive Director	14.4yrs	데이터 없음	46.4% HK$ 6.3b
Ming Ping Huang	Non-Executive Director	14.4yrs	CN¥150.00k	1.22% HK$ 165.4m
Yuanzhong Liu	Chairman of the Supervisory Committee	14.4yrs	데이터 없음	1.22% HK$ 165.4m
Lei Zhao	Independent Non-Executive Director	4.5yrs	CN¥150.00k	데이터 없음
Zhi Su	Independent Non-Executive Director	4.5yrs	CN¥150.00k	데이터 없음
Zhihong Jiang	Independent Non-Executive Director	4.5yrs	CN¥150.00k	데이터 없음
Yushe Yang	Independent Non-Executive Director	4.5yrs	CN¥150.00k	데이터 없음

11.1yrs

평균 재임 기간

52.5yo

평균 연령

경험이 풍부한 이사회: 6826 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.1 년).

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/27 22:21
장 마감 주가	2024/12/27 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Shanghai Haohai Biological Technology Co., Ltd. 17 애널리스트 중 1 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jingwei Qi	China Merchants Securities Co. Ltd.
Xiaofang Xu	Citic Securities Co., Ltd.
Eva Zhao	Citigroup Inc

Shanghai Haohai Biological Technology 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, May 29, 2024

Shanghai Haohai Biological Technology Co., Ltd. Announces Resignation of Guo Yongqing as Independent Non-Executive Director, Chairman of Audit Committee, Member of Remuneration and Appraisal Committee and Member of Nomination Committee

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 12, 2023

Less than half of directors are independent

Shanghai Haohai Biological Technology Co., Ltd. Announces Retirement of Li Yingqi as Independent Non-Executive Director

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 29, 2022

Recent updates

Shanghai Haohai Biological Technology Co., Ltd. to Report Fiscal Year 2024 Results on Mar 22, 2025

Third quarter 2024 earnings released: EPS: CN¥2.19 (vs CN¥0.36 in 3Q 2023)

Investor sentiment improves as stock rises 20%

Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Shanghai Haohai Biological Technology Co., Ltd. Approves Interim Dividend for the Six Months Ended 30 June 2024

Upcoming dividend of CN¥0.40 per share

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback for 2,229,405 shares, representing 0.95% for CNY 200 million.

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024

Shanghai Haohai Biological Technology Co., Ltd. Announces to Distribute A Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of CN¥1.00 per share

First quarter 2024 earnings released: EPS: CN¥0.58 (vs CN¥0.60 in 1Q 2023)

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, May 29, 2024

New major risk - Revenue and earnings growth

Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released

Now 28% overvalued

Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023

Shanghai Haohai Biological Technology Co., Ltd. Announces Resignation of Guo Yongqing as Independent Non-Executive Director, Chairman of Audit Committee, Member of Remuneration and Appraisal Committee and Member of Nomination Committee

Third quarter 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.32 in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Financial Guidance for the Nine Months Ended 30 September 2023

Investor sentiment improves as stock rises 15%

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback.

Second quarter 2023 earnings released: EPS: CN¥0.73 (vs CN¥0.059 in 2Q 2022)

Shanghai Haohai Biological Technology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Upcoming dividend of HK$0.44 per share at 1.4% yield

Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on August 11, 2023

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 12, 2023

First quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.35 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥1.04 (vs CN¥2.00 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released

Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.059 (vs CN¥0.76 in 2Q 2021)

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2022 Results on Aug 26, 2022

Shanghai Haohai Biological Technology Co., Ltd. Provides Financial Guidance for the Six Months Ended 30 June 2022

Upcoming dividend of HK$0.82 per share

Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2021

Investor sentiment improved over the past week

Shanghai Haohai Biological Technology Co., Ltd. Announces Retirement of Li Yingqi as Independent Non-Executive Director

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 29, 2022

Full year 2021 earnings released: EPS: CN¥2.00 (vs CN¥1.30 in FY 2020)

Less than half of directors are independent

Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2022 Results on Apr 29, 2022

Shanghai Haohai Biological Technology Co., Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2021

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues miss analyst expectations

Shanghai Haohai Biological Technology Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.50 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.76 (vs CN¥0.29 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ending June 30, 2021

Investor sentiment improved over the past week

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) entered into the share purchase agreement to acquire an additional 9% stake in Contamac Holdings Limited from John Alexander McGregor for £5.9 million.

First quarter 2021 earnings released: EPS CN¥0.55 (vs CN¥0.14 loss in 1Q 2020)

Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Earnings Guidance for the Three Months Ending March 31, 2021

Full year 2020 earnings released

Shanghai Haohai Biological Technology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 27, 2021

Investor sentiment deteriorated over the past week

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) signed the share transfer agreement to acquire 38.23% in Ouhua Meike (Tianjin) Medical Technology Co., Ltd. from Welly And Bloom Ltd and Refined Beauty By Beth Ltd for approximately CNY 140 million.

CEO 보상 분석

CEO

테뉴어

보상